Skip to main navigation
  • Contact
Aimmune
Menu CLOSE X
CLOSE X
  • About Aimmune
    • Company Overview
    • History
    • Leadership
    • Culture of Integrity
  • Investors & Media
    • Investor Overview
    • Press Releases
    • Financials & Filings
      • Annual Reports
      • SEC Filings
    • Corporate Governance
    • Stock Information
      • Stock Quote & Chart
      • Analyst Coverage
    • Investor FAQs
  • Careers
    • Career Opportunities
  • Contact

Press Releases

Keyword Search

Recent News

June 11, 2019
Aimmune Therapeutics Discusses AR101’s Cost-Effectiveness and Demonstrated Clinical Benefits at ICER Meeting
June 5, 2019
Aimmune to Participate in the Goldman Sachs 40th Annual Healthcare Conference
June 4, 2019
Data from Two Studies Confirm Quality of Life and Psychosocial Burden of Living with Peanut Allergy
June 4, 2019
New Data from Phase 3 PALISADE Follow-on Study of AR101 for Peanut Allergy Show Continued Immunomodulation Through Daily Dosing Beyond One Year
June 2, 2019
Pivotal Phase 3 ARTEMIS Trial Data Demonstrates Consistent Safety and Efficacy of AR101 in Children and Adolescents with Peanut Allergy
May 24, 2019
Aimmune to Present AR101 Data at European Academy of Allergy and Clinical Immunology 2019 Congress
May 21, 2019
New Study Shows More Than Half of Teens with Peanut Allergy Visited the E.R., More Than One-Third Required Hospitalization Due to Accidental Exposure to Peanut
May 16, 2019
Aimmune to Present at RBC Capital Markets Global Healthcare Conference
May 16, 2019
Aimmune Announces U.S. FDA Advisory Committee Meeting Date for AR101 for Peanut Allergy
May 8, 2019
Aimmune Therapeutics Announces First Quarter 2019 Financial Results and Provides Operational Highlights

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • Next page next ›
  • Last page last »

Investor and Media Contacts

Investors

DeDe Sheel
650-376-6492
dsheel@aimmune.com

Media

James Larkin
650-600-1385
jlarkin@aimmune.com

Shareholder Tools

  • Print Page
  • Email Alerts
  • IR Contact
  • RSS Feeds
About Aimmune
  • Company Overview
  • History
  • Leadership
  • Culture of Integrity
Investors & Media
  • Investor Overview
  • Press Releases
  • Financials & Filings
  • Corporate Governance
  • Stock Information
  • Investor FAQs
Careers
  • Career Opportunities
© 2019 Aimmune Therapeutics. All rights reserved.
  •  
  • Terms of Use
  • Privacy Policy
  • Privacy Shield
  • Twitter Guidelines
  • Facebook Guidelines
ShareThis Copy and Paste
Aimmune Therapeuticsat the Bank of America Merrill Lynch Healthcare Conference
Tuesday, May 16, 2017 1:00 p.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
— "Real-World" Trial Will Augment Ongoing Phase 3 PALISADE Trial to Support Regulatory Filings and Market Understanding — BRISBANE, Calif.--(BUSINESS WIRE)--May 11, 2017-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the Phase 3 RAMSES (ARC007) clinical trial of AR101 for treatment of peanut allergy. AR101 is Aimmune's investigational biologic oral immunotherapy for desensitization of patient...